Overview

A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Joel Lavine
Collaborator:
Raptor Pharmaceuticals Corp.
Treatments:
Cysteamine